Sab Biotherapeutics, Inc. (SABSW) — DEF 14A Filings
All DEF 14A filings from Sab Biotherapeutics, Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
SAB Biotherapeutics Seeks Shareholder Nod for Major Dilution, Equity Boost
— Aug 29, 2025 Risk: high
SAB Biotherapeutics, Inc. (SABSW) is calling a Special Meeting on September 26, 2025, to address two critical proposals impacting its capital structure and equi -
SAB Biotherapeutics Sets Virtual Annual Meeting for July 17
— Jun 2, 2025 Risk: low
SAB Biotherapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on June 2, 2025, for its Annual Meeting of Stockholders scheduled for July 17, 2025, at 1 -
SAB Biotherapeutics Files Definitive Proxy Statement
— May 30, 2024 Risk: medium
SAB Biotherapeutics, Inc. filed a definitive proxy statement (DEF 14A) on May 30, 2024, for its annual meeting of stockholders. The company, formerly known as B
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX